One study suggested that an Nrf2-mediated 17-gene signature can be used to distinguish TB patients from healthy controls, LTBI, pneumonia, or lung cancer, as well be used as an indicator of the anti-TB response (30). The gene discussed is NFE2L2; the disease is lung cancer.